CEO of ALK on Chinese waiver: ”Some of the best news ALK has had in years"

On Thursday, ALK reported that the Chinese health authorities has granted dispensation, allowing the company to file dust mite allergy treatment Acarizax for registration despite having an incomplete clinical study.
Photo: ALK / PR
Photo: ALK / PR
by marketwire, translated by daniel pedersen

”Some of the best news ALK has had in years,” ALK CEO Carsten Hellman tells MarketWire.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading